Scholar Rock Holding Corporation
SRRK
Rang in aandelen
#3426
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$41.58
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$5.06B
Verandering (1 dag)
3.34%
Verandering (1 jaar)
47.62%
Land
US
Handel Scholar Rock Holding Corporation (SRRK)
Categorie
Healthcare
P/B-ratio voor Scholar Rock Holding Corporation (SRRK)
P/B-ratio op October 2026 TTM: 20.38
Volgens de meest recente financiële rapporten en aandelenkoers van Scholar Rock Holding Corporation is de huidige P/B-ratio (TTM) 20.38. Eind 2023 had het bedrijf een P/B-ratio van 6.34.
P/B-ratiohistoriek voor Scholar Rock Holding Corporation van 2016 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 20.38 | 74.04% |
| 2024 | 11.71 | 84.56% |
| 2023 | 6.34 | 205.93% |
| 2022 | 2.07 | -60.88% |
| 2021 | 5.30 | -7.34% |
| 2020 | 5.72 | 77.92% |
| 2019 | 3.21 | -4.68% |
| 2018 | 3.37 | -165.04% |
| 2017 | -5.19 | -43.90% |
| 2016 | -9.24 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -69.33% |
US
|
|
| 13.2547 | -34.96% |
US
|
|
| 4.208 | -79.35% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -69.67% |
NL
|
